Indazole compounds acting as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors have been described in a recent Nippon Shinyaku Co. Ltd. patent as potentially useful for the treatment of irritable bowel syndrome, psoriasis, arthritis, bacterial infection, systemic lupus erythematosus, pancreatitis, asthma and chronic obstructive pulmonary disease, among others.
Haisco Pharmaceutical Group Co. Ltd. has described propionic acid derivatives acting as integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory disorders.
Suzhou Ark Biopharmaceutical Co. Ltd. researchers have prepared and tested heteroaromatic bicyclic compounds reported to be useful for the treatment of respiratory syncytial virus (RSV) infection.
Research at Korea Research Institute of Chemical Technology (KRICT) has led to the identification of pyrazolopyrimidine-containing compounds acting as dual specificity protein kinase TTK (MPS1; MPS1L1) inhibitors and reported to be useful for the treatment of cancer.
858 Therapeutics Inc. has patented a series of 6,6-fused heterocyclic compounds acting as N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of acute myeloid leukemia.
Sarcopenia is the loss of muscle mass typically in the elderly that ultimately reduces mobility, diminishes quality of life, and can cause potential fall-related injuries that can become serious. While exercise is an appropriate approach, unfortunately patients with underlying health conditions and low motivation are unlikely to adhere to regimented muscle training. Moreover, there are no available effective cures for addressing age-related muscle loss. Still, it is possible that a failure to repair muscle after injury may be a major contributor to muscle mass loss in the aged that can be addressed by using muscle stem cells.
Researchers from OSE Immunotherapeutics SA have published preclinical data for the novel anti-ChemR23 monoclonal antibody (MAb) (OSE-230) with anti-inflammatory properties, being evaluated for the potential treatment of cancer.
Researchers from Universita degli Studi di Pavia and affiliated organizations have presented the discovery of a novel sigma-1 receptor (S1R) antagonist, RC-752, being developed as an antinociceptive agent for the treatment of neuropathic pain.
Alexion, Astrazeneca Rare Disease, part of Astrazeneca plc, has entered a definitive purchase and license agreement for a portfolio of preclinical gene therapy programs and enabling technologies from Pfizer Inc.
RSS
